|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
NEOPLASIA
From the Academic Department of Haematology and
Cytogenetics, Institute of Cancer Research, Sutton, United Kingdom;
Institute of Human Genetics, University Hospital, Kiel, Germany;
Department of Pathology, British Columbia Cancer Agency, Vancouver,
Canada; Internal Medicine II, Kumamoto University School of Medicine,
Kumamoto, Japan; Oncology Institute of Southern Switzerland,
Bellinzona, Switzerland; Laboratory of Cytogenetics and Molecular
Genetics, Department of Pathology, Hospital del Mar IMAs IMIM,
Barcelona, Spain; and The Sanger Centre, Wellcome Trust Genome Campus,
Cambridge, United Kingdom.
Chromosomal translocation t(6;14)(p21.1;q32.3) has been reported as
a rare but recurrent event not only in myeloma and plasma cell leukemia
but also in diffuse large B-cell non-Hodgkin lymphoma (B-NHL)
(diffuse large B-cell lymphoma [DLBCL]) and splenic lymphoma with
villous lymphocytes (SLVL); however, the nature of the target gene(s)
has not been determined. This study identified t(6;14)(p21.1;q32.3) in
3 cases of transformed extranodal marginal zone B-NHL, in 1 case of
SLVL, and in 1 case of a low-grade B-cell lymphoproliferative disorder.
In a sixth case, a CD5+ DLBCL, the translocation was
identified by molecular cloning in the absence of cytogenetically
detectable change. Two chromosomal translocation breakpoints were
cloned by using long-distance inverse polymerase chain reaction
methods. Comparison with the genomic sequence for chromosome 6p21.1
showed breakpoints approximately 59 and 73.5 kilobases 5' of the cyclin
D3 (CCND3) gene with no other identifiable transcribed
sequences in the intervening region. Although Southern blotting with
derived genomic 6p21.1 probes failed to detect other rearrangements,
fluorescent in situ hybridization assays, using BAC (bacterial
artificial chromosome) clones spanning and flanking the
CCND3 locus, along with probes for IGH
confirmed localization of 6p21.1 breakpoints within the same region, as well as fusion of the CCND3 and IGH loci.
Furthermore, in all cases, high-level expression of CCND3
was demonstrated at RNA and/or protein levels by Northern and Western
blotting and by immunohistochemistry. These data implicate
CCND3 as a dominant oncogene in the pathogenesis and
transformation in several histologic subtypes of mature B-cell
malignancies with t(6;14)(p21.1;q32.3) and suggest that
CCND3 overexpression seen in about 10% of DLBCL cases may
have a genetic basis.
(Blood. 2001;98:2837-2844) The lymphomas and leukemias of mature B cells are a
biologically and histologically heterogeneous group of
malignancies.1 Their molecular pathogenesis for the most
part remains unknown, although cloning of chromosomal translocations
targeted to the immunoglobulin (IG) loci continues to allow
the identification of novel dominant oncogenes and to define new
pathogenic mechanisms.2 These translocations result in the
deregulated expression of genes involved in several pathways, including
the control of programmed cell death (apoptosis) and proliferation.
IG translocations that involve genes controlling
progression through the cell cycle have been described. Cyclin D1
(CCND1) on chromosome 11q13 is involved in the
t(11;14)(q13;q32.3). This translocation is found in nearly all cases of
mantle cell lymphoma but also in some cases of myeloma, in marginal
zone malignancies, such as splenic lymphoma with villous lymphocytes
(SLVL), and in B-cell prolymphocytic leukemia.3-6 The
cyclin-dependent kinase gene (CDK6) in chromosome band 7q22
is involved in t(7;14)(q22;q32) or more commonly in t(2;7)(p12;q22);
these translocations appear to be specific for a subset of
SLVL.7,8 The involvement of the cell-cycle regulatory
genes in marginal zone B-cell malignancies was unanticipated, because
they are characteristically indolent diseases. Whether these genes
might have functions in B-cell differentiation other than cell-cycle
regulation in mature B cells is not yet clear; cyclin D3 expression,
for example, is associated with differentiation of some cell
types.9
Cytogenetic abnormalities of chromosome band 6p21 reported in mature
B-cell malignancies are various and include translocations, amplifications, and deletions.10,11 Such translocations in diffuse large B-cell lymphoma (DLBCL) often involve the BCL6
gene on chromosome band 3q27 and may juxtapose BCL6 with
either the histone H4 gene or the PIM1
oncogene.12,13 The t(6;14)(p12~p21;q32) has been
previously reported in a variety of B-cell malignancies, principally in
myeloma and plasma cell leukemia but also in DLBCL and splenic marginal
zone lymphomas (SMZLs).14-18 Here we report the recurrent
involvement of a third cell-cycle regulatory gene, cyclin
D3/CCND3, in 6 cases of mature B-cell malignancy, including one case of CD5+ DLBCL, through its direct involvement in
t(6;14)(p21.1;q32.3).
Patient clinical characteristics
Cytogenetics
Long-distance inverse polymerase chain reaction Long-distance inverse polymerase chain reaction (LDI-PCR) and DNA sequencing of IGHJ rearrangements was performed as previously described.22 Primers designed to amplify illegitimate IG switch rearrangements observed with a 3' S probe on Southern blot were used. In case 1 from Table 1, DNA was
digested to completion with SphI and ligated at low
concentration, followed by nested PCR using R1 primer
(5'-GACCAGTGGACACTGTTCTCAGATGG-3') and F4 primer
(5'-CACGCAGAAGAGCCTCTCCCTGT-3') and R2 primer
(5'-CCTCCAAGGCCCTTTTCTTCTGTG-3') and F5 primer
(5'-CCCAGCATGGAAATAAAGCACCC-3'). In case 2 from Table 1, DNA was
digested with Taq1 and amplified first with primers R1
and F1 (5'-TCCCTGAGGTGGCACCGATG-3') and then in a second round of
amplification with primers R2 and F2
(5'-CCAGAGCTGAGGCCAAGCTAGAG-3'). The sizes of the PCR products obtained
(1.8 and 2.5 kilobases [kb], respectively) corresponded to the sizes
of the rearranged fragments seen on Southern blot (allowing for the
position of the LDI-PCR primers), indicating that neither fragment
arose because of PCR artifact.
Radiation hybrid mapping Radiation hybrid (RH) mapping was performed with DNA primers 1060 (5'-TCACCAGAGTTTACCCCTGT-3') and 1061 (5'-TGCATATACATCCATCCATGC-3') derived from the breakpoint sequence of the cloned LDI-PCR fragment from case 1 by means of the Stanford G3 Panel (Research Genetics, Huntsville, AL). Map localization was calculated on the Stanford Human Genome Center RH server.47Bacterial artificial chromosome and plasmid artificial chromosome screening and sequencing Bacterial artificial chromosome (BAC) and plasmid artificial chromosome (PAC) clones derived from the chromosome band 6p21 contig Chr_6ctg648 were screened by PCR, using primers 1060/1061. Positive clones were rescreened with a second primer pair derived from the same breakpoint sequence (1077, 5'-CATTGTATGGATGTATATGC-3'; 1078, 5'-TACAAAAGACCTGCTCAAGG-3'). Screening of a gridded PAC library was also performed by hybridization, using a single-copy probe derived from the breakpoint sequence.23 Positive clones were rehybridized twice with the breakpoint clone and with a CCND3 expressed sequence tag (EST) clone spanning the open reading frame to show colocalization of the cloned breakpoint with CCND3. The complete genomic sequence of the region around the CCND3 gene derived from clones RP11-533O20 and RP5-973N23 was obtained at the Sanger Centre, using methods previously described.24 The accession numbers for these finished sequences are AL513008 and AL160163, respectively.Fluorescence in situ hybridization studies Fluorescence in situ hybridization (FISH) for the detection of breakpoints in the IGH locus was performed, using the LSI IGH Break-apart probe (Vysis, Downers Grove, IL). For the detection of breaks affecting the CCND3 locus, 2 different interphase FISH assays were developed. The first involved the use of probes closely flanking the breakpoint cloned from the index patient 1; these should colocalize in normal cells but should be separated in cells carrying a CCND3 translocation. Pooled PAC clones RP1-321B9 and RP1-139D8 were chosen as centromeric and PAC RP5-973N23 and BAC RP11-298J23 as telomeric probes for this approach. The second assay aimed to identify fusion of chromosomal regions 6p21 and 14q32.3 by means of differently labeled probes spanning the CCND3 and IGH loci, respectively. These probes should be separated in normal cells but fused on both der(6)t(6;14)(p21.1;q32.3) and der(14)t(6;14)(p21.1;q32.3) by a t(6;14)(p21.1;q32.3) affecting IGH and CCND3. The CCND3 probes were PAC RP5-973N23 containing the CCND3 gene as well as the flanking clones RP1-321B9, RP1-139D8, and RP11-298J23. A pool of cosmids for the IGVH and IGC regions served as
probe for the IGH locus.25 PAC and BAC DNA was
prepared by using the Perfectprep Plasmid Maxi Kit (Eppendorf,
Cologne, Germany) and labeled with Spectrumgreen-dUTP and
Spectrumorange-dUTP (Vysis, Downers Grove, IL), respectively, using
random-primed DNA labeling (Life Technologies, Eggenstein, Germany).
Each PAC/BAC clone (200 ng) was coprecipitated with 5 µg Cot1 DNA
(Life Technologies) and dissolved in 10 µL hybridization buffer
containing 50% formamide, 10% dextran sulfate, and 2× sodium
chloride/sodium citrate. FISH was performed on cells left from
cytogenetic analysis or on cytospin preparations of cells stored in
dimethyl sulfoxide. Preparation of slides, pretreatment with pepsin,
and simultaneous denaturation and hybridization were performed as
described.20 Experiments were evaluated by using a
fluorescence microscope (Zeiss, Göttingen, Germany) equipped with
appropriate filter sets (AHF, Tübingen, Germany) and were
documented using the ISIS program (MetaSystems, Altlussheim, Germany).
Southern, Northern, and Western blots High molecular weight DNA obtained from all cases was Southern blotted and probed with the chromosome band 6p21 breakpoint clone derived from patient 1 and IGH probes using previously described methods and probes.26,27 Northern and Western blotting were performed as described.27 For Northern blotting, a 2.0-kb complementary DNA (cDNA) spanning the CCND3 open-reading frame from EST clone, IMAGE No. 2 015 357 was used. The cyclin D3 monoclonal antibody (Mab) was clone DCS22 (Oncogene Research Products, Boston, MA) and the p27Kip1 MAb was clone DCS72-F6 (Neomarkers, Freemont, CA).Immunohistochemistry Paraffin section and cytospin immunohistochemistry were performed by using routine methods. The cyclin D3 Mab was identical to that used for Western blots (clone DCS22). Immunostains were performed on an automated immunostainer (Ventana, Tucson, AZ) by using a streptavidin technique. The primary antibody was used at a 1:20 dilution with microwave antigen retrieval and citrate buffer, pH 6.0. Reactive tonsil was used as positive control and the negative control omitted the primary antibody.
Molecular cloning of t(6;14)(p21.1;q32.3) To detect IGH translocations in the absence of cytogenetic data, we have developed LDI-PCR methods to clone rearrangements involving the JH and S region segments of the IGH locus22 (T.S., T.G.W., M.J.S.D., unpublished data, December 2000). Translocations targeted to the S regions may also be detected by Southern blot as the lack of comigration of 5' and 3' rearranged IGHS fragments.26 We initially studied a case of aggressive CD5+ DLBCL in which cytogenetic studies had shown a complex karyotype with multiple structural abnormalities, including del(6p) but no cytogenetically obvious t(6;14)(p21.1;q32.3) (Table 1, patient 1).19 No suitable cytogenetic material was available from this case to permit more detailed FISH analysis on metaphase preparations. Analysis of the configuration of the IGH loci was performed, using both Southern blot and LDI-PCR methods. Southern blot showed 2 clonal IGHJ rearrangements; both were cloned by LDI-PCR and sequenced and showed productive VDJ and DJ rearrangements (data not shown). Further analysis of Southern blot with a panel of IGHS probes, including 5' and 3' S probes showed an illegitimate 3' S fragment of
4.2 kb in SphI digestion (Figure
1A). This fragment was cloned by using 3'
S LDI-PCR and sequenced (Accession No. AF388309); the sequence is
partially shown in Figure 1C. Beyond the S2 sequence, all
homology with the IGH locus was lost. Because the size of the amplified fragment corresponded to the size anticipated from the
Southern blotting experiments, it was unlikely to have been derived
from an LDI-PCR artifact. This finding was confirmed by showing
comigration of the rearranged illegitimate IGHS fragment with the rearranged fragment seen on Southern blot with the derived genomic probe (Figure 1B). At the time of cloning, this sequence had no
homology to any of the genomic or EST sequences on the public
databases.
Breakpoints of t(6;14)(p21.1;q32.3) lie 5' of the CCND3 gene To define the chromosomal localization of this novel sequence, RH mapping, BAC library screening using PCR primers, and screening of a gridded PAC library using a derived single-copy probe were performed. RH mapping of a sequence-tagged site derived from the LDI-PCR fragment placed the breakpoint on the short arm of chromosome 6 with SHGC-11207 being the most closely linked marker (distance 8cR, LOD-Score 14.09). The EST SHGC-11207 located in the interval between D6D1616 and D6S427 (59.6-73.9 cM) at 2422 cR10000 (F) represented the CCND3 gene.49 CCND3 has been cytogenetically assigned to the chromosomal region 6p12~21.1.28 Database searches using the BLAST algorithm50 revealed PAC clone RP5-973N23 to contain CCND3. This PAC clone is part of the contig Chr_6ctg6 established by the Sanger Center.48 BAC and PAC clones from Chr_6ctg6 covering more than 1 Mb around the CCND3 locus were screened by PCR and revealed only the one BAC clone (RP11-533O20) containing the translocation breakpoint. This clone contained the EST marker stSG8750 specific for the 3' end of CCND3. Furthermore, one of the isolated PAC clones hybridized not only with the translocation breakpoint probe but also with a CCND3 cDNA probe confirming that the 2 sequences were immediately adjacent. Restriction mapping with rare-cutting restriction enzymes indicated that the breakpoint clone was about 40 kb distant from the CCND3 gene (data not shown). To determine the precise relationship of the breakpoint to CCND3, the complete sequences of overlapping clones RP11-533O20 and RP5-973N23 were determined24 (and GenBank Accession No. AL513008 and AL160163). These data showed that the breakpoint in patient 1 lay approximately 59 kb 5' of the CCND3 coding sequences. Analysis of the intervening DNA sequence between the breakpoint and CCND3 failed to detect any other obvious transcribed DNA sequences.51To determine if other cases with cytogenetically defined
t(6;14)(p21.1;q32.3) also had breaks within the same region, Southern blotting was initially performed, using a genomic probe derived from
the breakpoint of the index patient. No additional breaks were
detected, suggesting that 6p21.1 breaks were dispersed. LDI-PCR cloning
and sequencing of case 2, Table 1, was therefore undertaken. As with
case 1, the breakpoint on chromosome 14 fell within IGHS, but in this case in S CCND3 is the target gene of t(6;14)(p21.1;q32.3) The close physical linkage of the breakpoints to CCND3, the lack of any obvious transcribed sequences in the intervening region, and the previous demonstration of involvement of other G1 cell-cycle regulatory proteins in B-cell malignancies suggested that CCND3 was the probable target gene of t(6;14)(p21.1;q32.3). To confirm this, Northern and Western blotting was performed in cases 1 and 2 in which there was suitable material available (Figure 2A-B). Marked overexpression of CCND3 RNA in case 1 and cyclin D3 protein in both cases were seen in comparison to other B-cell malignancies and lymphoid cell lines lacking cytogenetic abnormalities of chromosome band 6p21. Immunohistochemistry showed that all the neoplastic lymphoid cells expressed cyclin D3 (Figure 3A-B). Both cases also showed high-level expression of p27Kip1. Together, these data indicated that the illegitimate IGH S rearrangement in both cases represented a
t(6;14)(p21.1;q32.3), with breakpoints adjacent to CCND3,
resulting in deregulated expression of cyclin D3.
In other cases of t(6;14)(p21.1;q32.3) in which suitable material for blotting experiments was not available, expression of cyclin D3 protein was determined by using immunohistochemistry. Previous immunophenotypic studies on the expression of cyclin D3 in both normal and malignant B cells have demonstrated low-level expression usually in only a subpopulation of cells, which are thought to represent proliferating cells or blasts.30-33 With the exception of case 4, in which the translocation occurred in only a subpopulation of malignant cells, all cases with t(6;14)(p21.1;q32.3) showed high levels of expression of cyclin D3 in all the malignant cells (Figure 3). These data suggest the involvement of CCND3/cyclin D3 in these cases also; this finding was confirmed by the use of FISH assays described below. A series of lymphoid malignancies with cytogenetic abnormalities of chromosome band 6p21 other than t(6;14)(p21.1;q32.3), which were shown not to involve CCND3 by FISH, were also investigated for cyclin D3 expression by Western blot. All showed low levels of cyclin D3 expression, confirming the involvement of other genes in this region in B-cell malignancies (data not shown). t(6;14)(p21.1;q32.3) is a recurrent abnormality in mature B-cell malignancies t(6;14)(p21.1;q32.3) has been reported previously, mainly in cases of myeloma or plasma cell leukemia, although an association with SLVL has recently been reported.17 Material from these 3 cases of SLVL was not available for study. The same translocation was, however, identified in 4 additional cases from our cytogenetic databases; additional investigation of these cases was therefore undertaken. Morphologic review of all cases was performed by a hematopathologist (R.D.G.). A summary of the clinical details of all patients is shown in Table 1. In all but 2 patients, the karyotypes were very complex with multiple structural abnormalities. There were no other consistent associated cytogenetic abnormalities, but notably 3 of the 6 cases exhibited other chromosomal translocations involving 14q32, although the partner chromosomes were variable. In one case of SLVL (Table 1, case 3), t(6;14)(p21.1;q32.3) was the only detectable cytogenetic abnormality, suggesting that it may have been a primary event in the pathogenesis of the disease. This patient presented with a lymphocytosis of 30 × 109/L only, with the immunophenotype consistent with SLVL but with no lymphadenopathy or splenomegaly. However, in a case of SMZL with local transformation to DLBCL (Table 1, case 4), t(6;14)(p21.1;q32.3) was found only in the lymph nodal sample containing transformed cells and not in the splenic SMZL sample. Associated high-level expression of cyclin D3 was restricted to the subpopulation of large cells in the lymph node alone, suggesting that in this instance the translocation was a secondary event associated with transformation to high-grade disease. Two other cases (Table 1, cases 5 and 6) involved the salivary gland and shared identical histologic features. Both biopsies of the parotid gland showed a background histology compatible with a mucosa-associated lymphoid tissue (MALT) lymphoma, including reactive lymphoid follicles, lympho-epithelial lesions, and infiltrates of marginal zone B cells. Additionally, both cases had foci of large transformed cells consistent with diffuse large B-cell transformation; in both cases, the large transformed cells were strongly cyclin D3+ (Figure 3C-D). In case 2, an initial diagnosis of B-cell chronic lymphocytic leukemia (B-CLL) was made on the basis of the lymphocytosis and the concurrent presence of a t(14;19)(q32;q13), a translocation that is found predominantly, but not exclusively, in B-CLL.34 The bone marrow morphology in this case was, however, more suggestive of a lymphoplasmacytic lymphoma, including prominent infiltration of the squash preparations with mast cells. Immunophenotyping of peripheral blood lymphocytes showed expression of HLA-DR, CD19, CD20, CD22, CD38, FMC7, and sIgM but no expression of CD5, CD10, CD23, CD11c, or CD25.
No lymph node biopsy was performed, and the case was classified as a
low-grade B-cell lymphoproliferative disorder, not further classifiable.
t(6;14)(p21.1;q32.3) juxtaposes IGH and CCND3 A metaphase spread from case 5 is shown in Figure 4A. To confirm recurrent involvement of CCND3 and juxtaposition with IGH in these cases, 3 different interphase FISH assays were applied. Using the LSI IGH assay (Vysis), which includes differentially labeled probes hybridizing to the VH region and centromeric of the CH region, breakpoints within the IGH locus were confirmed in all 6 cases. Some of cases displayed complex signal patterns for this probe in metaphase and interphase cells, indicating different IGH-associated translocations as well as gains and losses of derivative chromosomes. To study involvement of the CCND3 locus in interphase nuclei a "CCND3 break-apart" assay was developed that applied differentially labeled probes flanking the breakpoint determined in case 1. The signals derived from these probes, which consisted of pooled BAC and PAC clones, should colocalize in cells with intact CCND3 locus but should be separated in cells carrying a translocation with breakpoint in the CCND3 locus (Figure 4B-D). By means of this assay, all 6 cases showed a signal pattern indicative of disruption of the CCND3 locus.
To demonstrate juxtaposition of the CCND3 and IGH loci, differentially labeled probe sets spanning the CCND3 and IGH loci, respectively, were applied in an interphase FISH assay. In this assay, a simple t(6;14)(p21.1;q32.3) in a diploid cell should result in a split of each one CCND3 and IGH signal, resulting in a total of 3 CCND3 and IGH signals. Moreover, each one of the different signals should be colocalized on the der(6)t(6;14)(p21.1;q32.3) and der(14)t(6;14)(p21.1;q32.3), leading to a signal pattern of 2 fusion signal plus each one CCND3 and IGH signal, the latter both indicating the normal chromosomes 6 and 14, respectively (Figure 4E-F). In all 5 cases with suitable material for this FISH assay available, fusion of IGH and CCND3 loci could be confirmed. Variant signal patterns were observed frequently (Figure 4 and data not shown). Review of the original cytogenetics of the index case (case 1), in the light of the above findings, failed to detect a t(6;14)(p21.1;q32.3); the case exhibited a highly complex karyotype19 (L. Harder, unpublished observations, December, 2000). Nevertheless, FISH not only unambiguously confirmed breakpoints in the CCND3 and IGH loci as well as IGH/CCND3 fusion in this case but also provided evidence for a gain of one intact copy of the CCND3 locus and loss of the der(6)t(6;14)(p21.1;q32.3) (Figure 4G and data not shown).
In this study, we demonstrate the recurrent involvement of the cyclin D3 gene in t(6;14)(p21.1;q32.3) of mature B-cell lymphoproliferative disorders; comparable results have been obtained by others in myeloma.29 In our series, the translocation was observed in patients with SLVL, MALT lymphoma at transformation to DLBCL, and in DLBCL. In the 2 cases cloned here, the IGH breakpoint occurred in the IG switch regions, whereas the breakpoints on chromosome 6p21.1 occurred some distance 5' of the CCND3 gene. Thus, both the anatomy of this translocation and its presence in several histologic subtypes of B-cell malignancy appear to be similar to the t(11;14)(q13;q32.3) involving the cyclin D1, which is found predominantly in mantle cell lymphoma but also in SLVL, B-cell prolymphocytic leukemia, and myeloma. The expression of all the D family of cyclins in both normal and malignant B-cell populations has been extensively studied by immunohistochemistry and at the RNA level30-33,35-38; the 2 may not necessarily parallel each other as cyclin D3 messenger RNA (mRNA) is subject to extensive posttranscriptional control.39 They comprise a group of molecules necessary for progression through the G1 phase of the cell cycle and are thought to have largely overlapping and possibly redundant roles. Cyclin D3 expression in reactive lymph nodes has been observed in the
blast cells of germinal centers and in interfollicular areas. cyclin
D3+ mantle and marginal zone cells were
BCL2 A genetic cause for cyclin D3 overexpression has long been suspected
but not previously demonstrated.40 Involvement of cyclin D2 in a translocation with the immunoglobulin Whether t(6;14)(p21.1;q32.3) is the only mechanism underlying high-level cyclin D3 expression in B-cell malignancies remains to be determined. High-level expression of cyclin D3 occurs in DLBCL at a frequency much higher than that reported to date for t(6;14)(p21.1;q32.3), although the complexity of the cytogenetic abnormalities may mask the translocation. Amplifications of 6p21 involving CCND3 and resulting in high-level expression have been described in other malignancies.43 Comparable amplifications of this region have been observed in comparative genomic hybridization studies of follicular lymphoma, although whether this involved CCND3 was not clear.11 Alternatively, more local alterations within the CCND3 gene may occur. As with CCND1 in mantle cell lymphoma, small deletions within the 3' untranslated regions of the CCND3 gene might allow changes in the levels of expression through increased mRNA stability.44,45 Finally, it is possible that high-level expression of cyclin D3, like p27Kip1, will be a useful prognostic marker, not only in DLBCL but also in other subtypes of B-cell malignancy.46
We thank all members of the chromosome 6 project group, in particular Sarah Sims and Sophie Williams, and the Human Genome Resource Centre, Hinxton Hall, United Kingdom, for EST, BAC, PAC, and cosmid clones. We thank Ms Claudia Becher, Dorit Schuster, Hiromi Ogata, and Marta Salido for skillful technical assistance. We thank Professor Hiroaki Mitsuya, Drs Shima Uneda, Hiroyuki Hata (Internal Medicine II, Kumamoto University), and Drs Kenichi Iyama and Jyunji Tsuruta (Department of Pathology, Kumamoto University Hospital) for their assistance in reporting the index case. We thank Dr Luisa Díaz Fernández for kindly providing one of the cases.
Submitted December 4, 2000; accepted June 28, 2001.
Supported by the Bud Flanagan Leukaemia Trust, the Kay Kendall Leukaemia Fund, the Lady Tata Memorial Trust, The Daiwa Anglo-Japanese Foundation, The Human Resources Support Foundation under Kumamoto City Municipal Centennial Commemorative Project, the Deutsche Krebshilfe (grant 10-1556-Schl4), and the IZKF, Kiel. R.D.G. and D.E.H. were supported by grant 5 U01 CA84967-02 from the National Institutes of Health. The Sanger Centre is funded by the Wellcome Trust.
R.S. and M.J.S.D. are co-senior authors.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Martin J. S. Dyer, Department of Haematology, University of Leicester, Robert Kilpatrick Clinical Sciences Building, Leicester Royal Infirmary, PO Box 65, Leicester, LE2 7LX United Kingdom; e-mail: mjsd1{at}le.ac.uk.
1.
Harris NL, Jaffe ES, Stein H, et al.
A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group.
Blood.
1994;84:1361-1392
2.
Willis TG, Dyer MJS.
The role of immunoglobulin translocations in the pathogenesis of B-cell malignancies.
Blood.
2000;96:808-822
3.
Rosenberg CL, Wong E, Petty EM, et al.
PRAD1, a candidate BCL1 oncogene: mapping and expression in centrocytic lymphoma.
Proc Natl Acad Sci U S A.
1991;88:9638-9642
4.
Vaandrager JW, Schuuring E, Zwikstra E, et al.
Direct visualization of dispersed 11q13 chromosomal translocations in mantle cell lymphoma by multicolor DNA fiber fluorescence in situ hybridization.
Blood.
1996;88:1177-1182
5.
Chesi M, Bergsagel PL, Brents LA, Smith CM, Gerhard DS, Kuehl WM.
Dysregulation of cyclin D1 by translocation into an IgH gamma switch region in two multiple myeloma cell lines.
Blood.
1996;88:674-681
6.
Jadayel D, Matutes E, Dyer MJS, et al.
Splenic lymphoma with villous lymphocytes: analysis of BCL1 rearrangements and expression of the cyclin D1 gene.
Blood.
1994;83:3664-3671 7. Corcoran MM, Mould SJ, Orchard JA, et al. Dysregulation of cyclin dependent kinase 6 expression in splenic marginal zone lymphoma through chromosome 7q translocations. Oncogene. 1999;18:6271-6277[CrossRef][Medline] [Order article via Infotrieve]. 8. Wahbi K, Hayette S, Callanan M, et al. Involvement of a human endogenous retroviral sequence (THE-7) in a t(7;14)(q21;q32) chromosomal translocation associated with a B cell chronic lymphocytic leukemia. Leukemia. 1997;11:1214-1219[CrossRef][Medline] [Order article via Infotrieve]. 9. Bartkova J, Lukas J, Strauss M, Bartek J. Cyclin D3: requirement for G1/S transition and high abundance in quiescent tissues suggest a dual role in proliferation and differentiation. Oncogene. 1998;17:1027-1037[CrossRef][Medline] [Order article via Infotrieve]. 10. Nagai H, Kinoshita T, Suzuki H, Hatano S, Murate T, Saito H. Identification and mapping of novel tumor suppressor loci on 6p in diffuse large B-cell non-Hodgkin's lymphoma. Genes Chromosomes Cancer. 1999;25:277-283[CrossRef][Medline] [Order article via Infotrieve].
11.
Bentz M, Werner CA, Dohner H, et al.
High incidence of chromosomal imbalances and gene amplifications in the classical follicular variant of follicle center lymphoma.
Blood.
1996;88:1437-1444
12.
Akasaka T, Miura I, Takahashi N, et al.
A recurring translocation, t(3;6)(q27;p21), in non-Hodgkin's lymphoma results in replacement of the 5' regulatory region of BCL6 with a novel H4 histone gene.
Cancer Res.
1997;57:7-12
13.
Akasaka H, Akasaka T, Kurata M, et al.
Molecular anatomy of BCL6 translocations revealed by long-distance polymerase chain reaction-based assays.
Cancer Res.
2000;60:2335-2341 14. Nishida K, Yashige H, Maekawa T, et al. Chromosome rearrangement, t(6;14)(p21.1;q32.3), in multiple myeloma. Br J Haematol. 1989;71:295-296[Medline] [Order article via Infotrieve].
15.
Taniwaki M, Nishida K, Takashima T, et al.
Nonrandom chromosomal rearrangements of 14q32.3 and 19p13.3 and preferential deletion of 1p in 21 patients with multiple myeloma and plasma cell leukemia.
Blood.
1994;84:2283-2290
16.
Sawyer JR, Lukacs JL, Munshi N, et al.
Identification of new nonrandom translocations in multiple myeloma with multicolor spectral karyotyping.
Blood.
1998;92:4269-4278 17. Sole F, Espinet B, Salido M, et al. Translocation t(6;14)(p12;q32): a novel cytogenetic abnormality in splenic lymphoma with villous lymphocytes. Br J Haematol. 2000;110:241-243[CrossRef][Medline] [Order article via Infotrieve]. 18. Cigudosa JC, Parsa NZ, Louie DC, et al. Cytogenetic analysis of 363 consecutively ascertained diffuse large B-cell lymphomas. Genes Chromosomes Cancer. 1999;25:123-133[CrossRef][Medline] [Order article via Infotrieve]. 19. Sonoki T, Matsuzaki H, Asou N, et al. Aggressive CD5-positive diffuse large B cell lymphoma showing c-myc rearrangements developed in a patient with autoimmune hemolytic anemia. Int J Hematol. 1996;63:71-76[CrossRef][Medline] [Order article via Infotrieve]. 20. Schlegelberger B, Metzke S, Harder S, Zühlke-Jenisch R, Zhang Y, Siebert R. Classical and molecular cytogenetics of tumor cells. In: Wegner RD, ed. Diagnostic Cytogenetics. Berlin, Germany: Springer-Verlag; 1999:151-185. 21. Mitelman F. ISCN: Guidelines for Cancer Cytogenetics, Supplement to an International System for Human Cytogenetic Nomenclature. Basel, Switzerland: Karger; 1995.
22.
Willis TG, Jadayel DM, Coignet LJA, et al.
Rapid amplification of rearrangements of the IGHJ locus by long-distance inverse PCR.
Blood.
1997;90:2456-2464
23.
Callanan MB, Le Baccon P, Mossuz P, et al.
The IgG Fc receptor, Fc 24. Bentley DR, Deloukas P, Dunham A, et al. The physical maps for sequencing human chromosomes 1, 6, 9, 10, 13, 20 and X. Nature. 2001;409:942-943[CrossRef][Medline] [Order article via Infotrieve]. 25. Rosenwald A, Ott G, Katzenberger T, et al. Jumping translocation of 1q as the sole aberration in a case of follicular lymphoma. Cancer Genet Cytogenet. 1999;108:53-56[CrossRef][Medline] [Order article via Infotrieve].
26.
Bergsagel PL, Chesi M, Nardini E, Brents LA, Kirby SL, Kuehl WM.
Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma.
Proc Natl Acad Sci U S A.
1996;93:13931-13936 27. Willis TG, Jadayel DM, Du MQ, et al. Bcl10 is involved in t(1;14)(p22;q32) of MALT B cell lymphoma and mutated in multiple tumor types. Cell. 1999;96:35-45[CrossRef][Medline] [Order article via Infotrieve]. 28. Inaba T, Matsushime H, Valentine M, Roussel MF, Sherr CJ, Look AT. Genomic organization, chromosomal localization, and independent expression of human cyclin D genes. Genomics. 1992;13:565-574[CrossRef][Medline] [Order article via Infotrieve].
29.
Shaughnessy J Jr, Gabrea A, Qi Y, et al.
Cyclin D3 at 6p21 is dysregulated by recurrent chromosomal translocations to immunoglobulin loci in multiple myeloma.
Blood.
2001;98:217-223
30.
Ott MM, Bartokova J, Bartek J, et al.
Cyclin D1 expression in mantle cell lymphoma is accompanied by downregulation of Cyclin D3 and is not related to proliferative activity.
Blood.
1997;90:3154-3159 31. Doglioni C, Chiarelli C, Macri E, et al. Cyclin D3 expression in normal, reactive and neoplastic tissues. J Pathol. 1998;185:159-166[CrossRef][Medline] [Order article via Infotrieve].
32.
Sanchez-Beato M, Camacho FI, Martinez-Montero JC, et al.
Anomalous high p27/KIP1 expression in a subset of aggressive B-cell lymphomas is associated with cyclin D3 overexpression: p27/KIP1-cyclin D3 colocalization in tumor cells.
Blood.
1999;94:765-772 33. Teramoto N, Pokrovskaja K, Szekely L, et al. Expression of cyclin D2 and D3 in lymphoid lesions. Int J Cancer. 1999;81:543-550[CrossRef][Medline] [Order article via Infotrieve]. 34. McKeithan TW, Takimoto GS, Ohno H, et al. BCL3 rearrangements and t(14;19) in chronic lymphocytic leukemia and other B-cell malignancies: a molecular and cytogenetic study. Genes Chromosomes Cancer. 1997;20:64-72[CrossRef][Medline] [Order article via Infotrieve].
35.
Delmer A, Ajchenbaum-Cymbalista F, Ramond S, Faussat A-M, Marie J-P, Zittoun P.
Overexpression of Cyclin D2 in chronic B-cell malignancies.
Blood.
1995;85:2870-2876 36. Suzuki R, Kuroda H, Komatsu H, et al. Selective usage of D-type cyclins in lymphoid malignancies. Leukemia. 1999;13:1335-1342[CrossRef][Medline] [Order article via Infotrieve]. 37. Moller MB, Kania PW, Ino Y, et al. Frequent disruption of the RB1 pathway in diffuse large B cell lymphoma: prognostic significance of E2F-1 and p16INK4A. Leukemia. 2000;14:898-904[CrossRef][Medline] [Order article via Infotrieve]. 38. Sola B, Roue G, Duquesne F, et al. Expression of cyclins D-type in B-chronic lymphoproliferative disorders. Leukemia. 2000;14:1318-1319[CrossRef][Medline] [Order article via Infotrieve]. 39. Naderi S, Gützow KB, Christoffersen J, Smeland EB, Blomhoff HK. cAMP-mediated growth inhibition of lymphoid cells in G1: rapid down-regulation of Cyclin D3 at the level of translation. Eur J Immunol. 2000;30:1757-1768[CrossRef][Medline] [Order article via Infotrieve]. 40. Hunter T, Pines J. Cyclins and cancer. Cell. 1991;66:1071-1074[CrossRef][Medline] [Order article via Infotrieve]. 41. Qian L, Gong J, Liu J, Broome JD, Koduru PR. Cyclin D2 promoter disrupted by t(12;22)(p13;q11.2) during transformation of chronic lymphocytic leukaemia to non-Hodgkin's lymphoma. Br J Haematol. 1999;106:477-485[CrossRef][Medline] [Order article via Infotrieve].
42.
Solvason N, Wu WW, Parry D, et al.
Cyclin D2 is essential for BCR-mediated proliferation and CD5 B cell development.
Int Immunol.
2000;12:631-638 43. Kuchiki H, Saino M, Nobukuni T, et al. Detection of amplification of a chromosomal fragment at 6p21 including the cyclin D3 gene in a glioblastoma cell line by arbitrarily primed polymerase chain reaction. Int J Cancer. 2000;85:113-116[CrossRef][Medline] [Order article via Infotrieve].
44.
Rimokh R, Berger F, Bastard C, et al.
Rearrangement of CCND1 (BCL1/PRAD1) 3' untranslated region in mantle-cell lymphomas and t(11q13)-associated leukemias.
Blood.
1994;83:3689-3696 45. de Boer CJ, Vaandrager JW, van Krieken JH, Holmes Z, Kluin PM, Schuuring E. Visualization of mono-allelic chromosomal aberrations 3' and 5' of the cyclin D1 gene in mantle cell lymphoma using DNA fiber fluorescence in situ hybridization. Oncogene. 1997;15:1599-1603[CrossRef][Medline] [Order article via Infotrieve]. 46. Saez A, Sanchez E, Sanchez-Beato M, et al. p27KIP1 is abnormally expressed in diffuse large B-cell lymphomas and is associated with an adverse clinical outcome. Br J Cancer. 1999;80:1427-1434[CrossRef][Medline] [Order article via Infotrieve]. 47. Stanford Human Genome Center. Available at: http://www-shgc.stanford.edu/RH/rhserverformnew.html. Accessed July 2000. 48. Sanger Centre Web site. Available at: http://www.sanger.ac.uk/HGP/Chr6/. Accessed July 2000. 49. Genemap99 RH map. Available at: http://www.ncbi.nlm.nih.gov/genemap99/. Accessed July 2000. 50. National Center for Biotechnology Information. Available at: http://www.ncbi.nlm.nih.gov. Accessed July 2000. 51. Genscan. Available at: http://genes.mit.edu/GENSCAN.html. Accessed April 2001.
© 2001 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  I. Nagel, T. Akasaka, W. Klapper, S. Gesk, S. Bottcher, M. Ritgen, L. Harder, M. Kneba, M. J.S. Dyer, and R. Siebert Identification of the gene encoding cyclin E1 (CCNE1) as a novel IGH translocation partner in t(14;19)(q32;q12) in diffuse large B-cell lymphoma Haematologica, July 1, 2009; 94(7): 1020 - 1023. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Wlodarska, D. Dierickx, V. Vanhentenrijk, K. Van Roosbroeck, H. Pospisilova, F. Minnei, G. Verhoef, J. Thomas, P. Vandenberghe, and C. De Wolf-Peeters Translocations targeting CCND2, CCND3, and MYCN do occur in t(11;14)-negative mantle cell lymphomas Blood, June 15, 2008; 111(12): 5683 - 5690. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Nakamura, H. Ye, C. M. Bacon, A. Goatly, H. Liu, L. Kerr, A. H. Banham, B. Streubel, T. Yao, M. Tsuneyoshi, et al. Translocations Involving the Immunoglobulin Heavy Chain Gene Locus Predict Better Survival in Gastric Diffuse Large B-Cell Lymphoma Clin. Cancer Res., May 15, 2008; 14(10): 3002 - 3010. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Fu, D. D. Weisenburger, T. C. Greiner, S. Dave, G. Wright, A. Rosenwald, M. Chiorazzi, J. Iqbal, S. Gesk, R. Siebert, et al. Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling Blood, December 15, 2005; 106(13): 4315 - 4321. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. F. Peterson, A. Boyapati, V. Ranganathan, A. Iwama, D. G. Tenen, S. Tsai, and D.-E. Zhang The Hematopoietic Transcription Factor AML1 (RUNX1) Is Negatively Regulated by the Cell Cycle Protein Cyclin D3 Mol. Cell. Biol., December 1, 2005; 25(23): 10205 - 10219. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Kasugai, H. Tagawa, Y. Kameoka, Y. Morishima, S. Nakamura, and M. Seto Identification of CCND3 and BYSL as Candidate Targets for the 6p21 Amplification in Diffuse Large B-Cell Lymphoma Clin. Cancer Res., December 1, 2005; 11(23): 8265 - 8272. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Pruneri, L. Pignataro, S. Valentini, S. Fabris, P. Maisonneuve, N. Carboni, S. Pece, M. Capra, B. Del Curto, A. Neri, et al. Cyclin D3 Immunoreactivity Is an Independent Predictor of Survival in Laryngeal Squamous Cell Carcinoma Clin. Cancer Res., January 1, 2005; 11(1): 242 - 248. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Troen, V. Nygaard, T.-K. Jenssen, I. M. Ikonomou, A. Tierens, E. Matutes, A. Gruszka-Westwood, D. Catovsky, O. Myklebost, G. Lauritzsen, et al. Constitutive Expression of the AP-1 Transcription Factors c-jun, junD, junB, and c-fos and the Marginal Zone B-Cell Transcription Factor Notch2 in Splenic Marginal Zone Lymphoma J. Mol. Diagn., November 1, 2004; 6(4): 297 - 307. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Song, J. Cooperman, D. L. Letting, G. A. Blobel, and J. K. Choi Identification of Cyclin D3 as a Direct Target of E2A Using DamID Mol. Cell. Biol., October 1, 2004; 24(19): 8790 - 8802. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Sanchez-Izquierdo, G. Buchonnet, R. Siebert, R. D. Gascoyne, J. Climent, L. Karran, M. Marin, D. Blesa, D. Horsman, A. Rosenwald, et al. MALT1 is deregulated by both chromosomal translocation and amplification in B-cell non-Hodgkin lymphoma Blood, June 1, 2003; 101(11): 4539 - 4546. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Martinez-Climent, A. A. Alizadeh, R. Segraves, D. Blesa, F. Rubio-Moscardo, D. G. Albertson, J. Garcia-Conde, M. J. S. Dyer, R. Levy, D. Pinkel, et al. Transformation of follicular lymphoma to diffuse large cell lymphoma is associated with a heterogeneous set of DNA copy number and gene expression alterations Blood, April 15, 2003; 101(8): 3109 - 3117. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Zhang, C.-Y. Yu, and B. Singer Cell and tumor classification using gene expression data: Construction of forests PNAS, April 1, 2003; 100(7): 4168 - 4172. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Franco, A. M. Florena, and E. Iannitto Splenic marginal zone lymphoma Blood, April 1, 2003; 101(7): 2464 - 2472. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Sanchez-Beato, A. Sanchez-Aguilera, and M. A. Piris Cell cycle deregulation in B-cell lymphomas Blood, February 15, 2003; 101(4): 1220 - 1235. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Satterwhite, T. Sonoki, T. G. Willis, L. Harder, R. Nowak, E. L. Arriola, H. Liu, H. P. Price, S. Gesk, D. Steinemann, et al. The BCL11 gene family: involvement of BCL11A in lymphoid malignancies Blood, December 1, 2001; 98(12): 3413 - 3420. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2001 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
, indicating that they represent activated
blast cells and suggesting a link between B-cell proliferation and
cyclin D3 expression.
light chain locus has
been shown in a case of Richter transformation of B-CLL.